Accurate Visualization of C4d Complement Fragment in Immunohistochemistry by C-Terminal Linear Neoepitope-Specific Antibodies
- PMID: 39408855
- PMCID: PMC11476897
- DOI: 10.3390/ijms251910526
Accurate Visualization of C4d Complement Fragment in Immunohistochemistry by C-Terminal Linear Neoepitope-Specific Antibodies
Abstract
C4d is the end degradation product of activated complement component C4b that appears during the early steps of the classical and lectin complement pathways. Within the primary sequence of C4d, there is a reactive thioester group that binds covalently to nearby surfaces, thus labeling the locations of complement activation. This feature makes C4d a target for immunohistochemical staining aimed to aid the diagnosis of, among others, the antibody-mediated rejection of transplanted organs, membranous glomerulonephritis, bullous pemphigoid, or inflammatory myopathies. However, the credibility of C4d immunostaining is debatable, as a high background in surrounding tissues and body fluids and diffused patterns of deposits in target structures are experienced with some of the available anti-C4d antibodies. Herein, we present an improved version of a rabbit anti-C4d antibody, originally raised against the C-terminal linear neoepitope of this complement fragment. Minor cross-reactivity with C4b and native C4 proteins, measured by ELISAs, as well as relatively low concentrations necessary for obtaining a specific signal in immunohistochemical analyses of formalin-fixed paraffin-embedded material, makes the improved antibody superior to commercially available rabbit monoclonal anti-C4d antibody SP91 dedicated to ex vivo diagnostics, as demonstrated by the staining of a panel of kidney transplant biopsies.
Keywords: C4d staining; antibody-mediated rejection; complement C4d; immunohistochemistry.
Conflict of interest statement
A.B. and M.O. are named as inventors in the European patent “ANTIBODIES SPECIFIC FOR COMPLEMENT COMPONENT C4D AND USES THEREOF” (EP 3 191 509 B1) and receive royalties from the Svar Life Science AB company that commercialized the product. The rest of the authors declare no conflicts of interest.
Figures

Similar articles
-
C4d as a diagnostic tool in membranous nephropathy.Nefrologia. 2012 May 14;32(3):295-9. doi: 10.3265/Nefrologia.pre2012.Feb.11224. Nefrologia. 2012. PMID: 22592419 English, Spanish.
-
Global quality assessment of liver allograft C4d staining during acute antibody-mediated rejection in formalin-fixed, paraffin-embedded tissue.Hum Pathol. 2018 Mar;73:144-155. doi: 10.1016/j.humpath.2017.12.007. Epub 2017 Dec 27. Hum Pathol. 2018. PMID: 29288041
-
Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection.Transpl Immunol. 2012 Jan;26(1):62-9. doi: 10.1016/j.trim.2011.08.005. Epub 2011 Sep 1. Transpl Immunol. 2012. PMID: 21907804
-
The importance of C4d in biopsies of kidney transplant recipients.Clin Dev Immunol. 2013;2013:678180. doi: 10.1155/2013/678180. Epub 2013 Jul 9. Clin Dev Immunol. 2013. PMID: 23935649 Free PMC article. Review.
-
The diagnostic significance of C4d deposits, as an immunohistochemical proof of complement activation, in kidney glomerular pathologies and kidney transplantation.Bratisl Lek Listy. 2024;125(5):275-280. doi: 10.4149/BLL_2024_41. Bratisl Lek Listy. 2024. PMID: 38624051 Review.
Cited by
-
The role of C4d expression in the diagnosis of bullous pemphigoid: a clinical and histopathological study.Arch Dermatol Res. 2025 Mar 17;317(1):569. doi: 10.1007/s00403-025-04031-2. Arch Dermatol Res. 2025. PMID: 40095080
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous